{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:25:50Z","timestamp":1777933550977,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.cllc.2023.06.011","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:40:39Z","timestamp":1687264839000},"page":"613-620","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4741-7463","authenticated-orcid":false,"given":"Matthew Z","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aanika","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph C","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua E","family":"Reuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema Mehta","family":"Steinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7689","key":"10.1016\/j.cllc.2023.06.011_bib0001","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cllc.2023.06.011_bib0002","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.thorsurg.2020.01.001","article-title":"Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer","volume":"30","author":"Broderick","year":"2020","journal-title":"Thorac Surg Clin"},{"issue":"suppl_4","key":"10.1016\/j.cllc.2023.06.011_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/41.suppl_4.1","article-title":"Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies","volume":"41","author":"Bow","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cllc.2023.06.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102109","article-title":"Association of immune checkpoint inhibitors with respiratory infections: a review","volume":"90","author":"Hamashima","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.cllc.2023.06.011_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2051-1426-2-19","article-title":"Opportunistic infections in patients treated with immunotherapy for cancer","volume":"2","author":"Kyi","year":"2014","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2023.06.011_bib0006","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/1759-7714.13422","article-title":"Opportunistic infections complicating immunotherapy for non-small cell lung cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2023.06.011_bib0007","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.cllc.2023.06.011_bib0008","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cllc.2023.06.011_bib0009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.cllc.2023.06.011_bib0010","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2020.09.025","article-title":"Infectious complications in patients treated with immune checkpoint inhibitors","volume":"141","author":"Karam","year":"2020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2023.06.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"17","key":"10.1016\/j.cllc.2023.06.011_bib0012","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.06.011_bib0013","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events version 5. Published online November 27, 2017 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"4","key":"10.1016\/j.cllc.2023.06.011_bib0014","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, nccn clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.cllc.2023.06.011_bib0015","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2018.7268","article-title":"A multidisciplinary toxicity team for cancer immunotherapy\u2013related adverse events","volume":"17","author":"Naidoo","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cllc.2023.06.011_bib0016","doi-asserted-by":"crossref","first-page":"w14281","DOI":"10.4414\/smw.2016.14281","article-title":"Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and pneumocystis pneumonia","volume":"22","author":"Schmiedel","year":"2016","journal-title":"Swiss Med Wkly"},{"issue":"8","key":"10.1016\/j.cllc.2023.06.011_bib0017","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1060028016650107","article-title":"Pneumocystis jirovecii pneumonia in the non-HIV-infected population","volume":"50","author":"Avino","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.cllc.2023.06.011_bib0018","doi-asserted-by":"crossref","first-page":"e00289","DOI":"10.1002\/rcr2.289","article-title":"Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab: nivolumab-induced aspergillosis","volume":"6","author":"Uchida","year":"2018","journal-title":"Respirol Case Rep"},{"issue":"5","key":"10.1016\/j.cllc.2023.06.011_bib0019","doi-asserted-by":"crossref","first-page":"e00580","DOI":"10.1002\/rcr2.580","article-title":"Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab","volume":"8","author":"Taima","year":"2020","journal-title":"Respirol Case Rep"},{"issue":"10","key":"10.1016\/j.cllc.2023.06.011_bib0020","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/infdis\/jix469","article-title":"Aspergillus fumigatus cell wall \u03b1-(1,3)-glucan stimulates regulatory T-cell polarization by inducing PD-L1 expression on human dendritic cells","volume":"216","author":"Stephen-Victor","year":"2017","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.cllc.2023.06.011_bib0021","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.lungcan.2008.03.015","article-title":"Risk factors for bacterial pneumonia after cytotoxic chemotherapy in advanced lung cancer patients","volume":"62","author":"Lee","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2023.06.011_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1005626","article-title":"Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: an analysis from the Italian pharmacovigilance database","volume":"12","author":"Barbieri","year":"2022","journal-title":"Front Oncol"},{"issue":"34","key":"10.1016\/j.cllc.2023.06.011_bib0023","doi-asserted-by":"crossref","first-page":"e21826","DOI":"10.1097\/MD.0000000000021826","article-title":"The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: a PRISMA-compliant systematic review and meta-analysis","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.cllc.2023.06.011_bib0024","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.pulmoe.2022.04.005","article-title":"Osimertinib-induced lymphocytopenia and pneumocystis jirovecii pneumonia","volume":"28","author":"Takechi","year":"2022","journal-title":"Pulmonology"},{"issue":"3","key":"10.1016\/j.cllc.2023.06.011_bib0025","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/1759-7714.13313","article-title":"Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections","volume":"11","author":"Lu","year":"2020","journal-title":"Thorac Cancer"},{"issue":"7","key":"10.1016\/j.cllc.2023.06.011_bib0026","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jtho.2020.03.002","article-title":"NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis","volume":"15","author":"Lurienne","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"3.5","key":"10.1016\/j.cllc.2023.06.011_bib0027","doi-asserted-by":"crossref","first-page":"QIM21","DOI":"10.6004\/jnccn.2020.7766","article-title":"QIM21-090: the expanding role of an oncology urgent care clinic for the management of immune-related adverse events","volume":"19","author":"Liang K","year":"2021","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423001377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:15:03Z","timestamp":1761506103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423001377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1525730423001377"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.06.011","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}